Home
overview

SMi is proud to present the New RNA Therapeutics Focus Day - Oligonucleotide Delivery Systems.


Introducing the only RNA therapeutics conference to hold a full day exploring alternatives to oligonucleotide delivery systems. With the global antisense and RNA therapeutics market size is expected to expand at a compound annual growth rate (CAGR) of 8.6% between 2019 and 2025, projected to reach $1.81 billion, this focus day will assess the growing need for research and development of novel delivery approaches to expand the current delivery methods in today's market.


In conjunction with Europe’s leading RNA therapeutics conference, we will explore new discoveries in novel drug delivery through case studies, regulatory outlooks and industry examples to give a comprehensive overview of the oligonucleotide delivery space.


This focus day offers you peer-to-peer networking with Global Product Managers, Heads of Drug Development, Senior Directors, Heads of Research and Development and many more.


We look forward to welcoming you to the conference in February.


Early registration is strongly advised to avoid disappointment.
 

Key Job Titles include:

Research & Development Directors/Managers/Scientists
Heads of Clinical Development
Heads of Pre-Clinical Development
Head of RNA Biology
Head of RNA Formulation and Drug Delivery
Head of Pre-clinical R&D
Head of New Modalities
Head of Discovery
Senior Scientists
Chief Scientific Officers
Chief Medical Officers


Global Presence:

Attendees from all over the world attend our events, gain hands on insight from representatives from UK, Europe and USA.
 

Accanis Therapeutics; Advanced Cell Diagnostics – A Bio-Techne Brand; Aescap 2.0; Alnylam Pharmaceuticals UK & Ireland; AmpTec GmbH; Aseptic Technologies SA; AstraZeneca; Bachem AG; BianoGMP; BioNTech IMFS GmbH; BioNTech RNA Pharmaceuticals; Boehringer Ingelheim Pharma GmbH & Co. KG; Calithera Biosciences; CEPI - Coalition for Epimemic Prepardness Innovation; Chemgenes Corporation; Curevac Ag; Dicerna Therapeutics.; Duke University School of Medicine; Ethris GmbH; Exicure Inc.; F.Hoffmann-La Roche AG; GSK; Horizon Discovery; InteRNA Technologies BV; Intertek; Lipocalyx; MedImmune; MHRA; MiNA Therapeutics; N4 Pharma UK Limited; New England Biolabs; NHS Blood and Transplant Authority; Nitto Avecia; NOF Europe GmbH; Nouscom SRL; ProQR Therapeutics; RCSI; RCSI Royal College of Surgeons in Ireland,; RNA Medco; ROCHE; Roche Diagnostics Deutschland GmbH; Roche Innovation Center; Russell Publishing Ltd; Sanofi; Sanofi-Aventis Deutschland GmbH; Takeda Development Centre Europe Ltd.; TCR Solutions; The Italian Institute of Technology; The RNA Medicines Company; Thermo Fisher Scientific; University Medicine Mainz Hospital; University Of Portsmouth; University Of Surrey; Yuria Pharma;
 

Focus Day programme

8:30 Registration & Coffee

9:00 Chair's Opening Remarks

Shalini Andersson

Shalini Andersson, Chief Scientist New Therapeutic Modalities, AstraZeneca
View Bio

9:10 Optimizing Nanoparticle mediated delivery of siRNAs to treat cancer and fibrosis

David Evans

David Evans, Chief Scientific Officer, Sirnaomics, Inc
View Bio

• Presenting a polypeptide nanoparticle mediated delivery system for siRNA therapeutics to treat cancer and fibrosis
• The benefits of the ability to deliver multiple siRNAs within the tumour microenvironment will be discussed
• Leveraging this capability to improve outcomes with Immune Checkpoint inhibitors
• Improved GMP manufacturing approaches using microfluidics for clinical development
 

9:50 Development of a light-triggered liposomes for intracellular oligonucleotide delivery to the retina

Enrico Mastrobattista

Enrico Mastrobattista, Professor of Pharmaceutical Biotechnology & Delivery, Utrecht University
View Bio

• Inherent challenges in oligonucleotide-based drug delivery modes
• Achieving an efficient and safe intracellular liposomal delivery system activated by light
• Discuss the methods, results and opportunities
• Discuss an ex vivo perfused eye model for ocular delivery of ON
 

10:30 Morning Coffee

11:00 Design of Safe and Potent Nucleic Acid Therapeutics

Ed Yaworski

Ed Yaworski, VP, Pharmaceutical Development, Genevant Sciences
View Bio

• Review of important elements of lipid nanoparticle technology
• Abrogation of common NA-LNP tolerability concerns
• Optimization of systemic mRNA therapeutics
 

11:40 Addressing the challenge of chronic dosing via traditional LNP-based delivery for mRNA therapeutics

Shalini Andersson

Shalini Andersson, Chief Scientist New Therapeutic Modalities, AstraZeneca
View Bio

• Clinical appeal of lipid nanoparticle delivery systems and other competing modes of delivery
• Challenges in production and screening of LNP candidates for effective translation to biotherapeutics
• Complications of chronic dosing and acceptable tolerability profiles
• Showcasing the development of a tolerable subcutaneous administration of mRNA via functionalized LNPs
 

12:20 Networking Lunch

13:20 Exploring the development and progress of BioNTech mRNA therapeutic delivery platforms

Heinrich Haas

Heinrich Haas, VP RNA Formulation and Drug Developement , BioNTech RNA Pharmaceuticals
View Bio

14:00 Aiming at delivering RNA to tumors using intra-venous injections

Steve Pascolo

Steve Pascolo, Founder and CEO, Miescher Pharma GmbH
View Bio

• Types of anti-cancer RNA requiring delivery to tumors
• Reported and original formulations: biodistribution in tumor bearing mice
• In vivo efficacy of formulated anti-cancer RNA

14:40 Overcoming lung barriers to siRNA delivery in cystic fibrosis through tailored lipid/polymer hybrid nanoparticles

Francesca Ungaro

Francesca Ungaro, Associate Professor, University Of Napoli Federico Ii
View Bio

• Non-Cellular and cellular barriers to inhaled siRNA in cystic fibrosis
• Strategies to engineer nanoparticles to overcome lung barriers
• In vitro and in vivo efficacy of inhalable hybrid lipid/polymer nanoparticles for siRNA delivery in cystic fibrosis
 

15:20 Afternoon Tea

15:50 Advanced microscopy methods to monitor RNA encapsulation and nanoparticle stability in biological environments

Katrien Remaut

Katrien Remaut, Associate Professor, Ghent University
View Bio

• Fluorescence correlation spectroscopy (FCS) to monitor RNA (mRNA, siRNA) encapsulation in nanoparticles
• RNA release and degradation in biological fluids
• Intracellular dissociation and degradation kinetics
 

16:30 Panel Discussion: Discussing the ongoing challenges of oligonucleotide delivery

• Questions around conjugation versus encapsulation; benefits and drawbacks
• Details and concerns behind the interactions between payloads and delivery vehicles
• Factors influencing the ratio between payload and delivery vehicle – what is an optimal ratio?
• Lipid-based encapsulation versus other nanoparticles
• Regulatory implications regarding production and quality; CMC and manufacturing
• Where is the next success in extrahepatic delivery?
 

Heinrich Haas

Heinrich Haas, VP RNA Formulation and Drug Developement , BioNTech RNA Pharmaceuticals
View Bio

David Evans

David Evans, Chief Scientific Officer, Sirnaomics, Inc
View Bio

David  Blakey

David Blakey, Chief Scientific Officer, MiNA Therapeutics

Bo Rode Hansen

Bo Rode Hansen, President & CEO, Genevant Sciences

Antonin de Fougerolles

Antonin de Fougerolles, CEO, Evox Therapeutics Ltd

17:30 Chair’s Closing Remarks and Close of Focus Day

+

FEATURED SPEAKERS

David Evans

David Evans

Chief Scientific Officer, Sirnaomics, Inc
Ed Yaworski

Ed Yaworski

VP, Pharmaceutical Development, Genevant Sciences
Enrico Mastrobattista

Enrico Mastrobattista

Professor of Pharmaceutical Biotechnology & Delivery, Utrecht University
Francesca Ungaro

Francesca Ungaro

Associate Professor, University Of Napoli Federico Ii
Heinrich Haas

Heinrich Haas

VP RNA Formulation and Drug Developement , BioNTech RNA Pharmaceuticals
Katrien Remaut

Katrien Remaut

Associate Professor, Ghent University
Shalini Andersson

Shalini Andersson

Chief Scientist New Therapeutic Modalities, AstraZeneca
Steve Pascolo

Steve Pascolo

Founder and CEO, Miescher Pharma GmbH

Antonin de Fougerolles

CEO, Evox Therapeutics Ltd
Antonin de Fougerolles

Bo Rode Hansen

President & CEO, Genevant Sciences
Bo Rode Hansen

David Blakey

Chief Scientific Officer, MiNA Therapeutics
David  Blakey

David Evans

Chief Scientific Officer, Sirnaomics, Inc
David Evans

Dr. David Evans obtained his BSc and PhD from Imperial College, London. His focus has been building scientific research teams focused on target validation and drug discovery – primarily in Oncology. David previously worked in the Boston area at Millennium Pharmaceuticals and Serono Pharmaceuticals and has over 15 years’ experience in the RNAi field. David cofounded Sirnaomics to develop siRNA therapeutics and is CSO for the company. Sirnaomics has its HQ in Gaithersburg, Maryland and labs in Suzhou and Guangzhou, China. Sirnaomics is using its polypeptide nanoparticle system to deliver siRNAs to treat cancer and fibrotic diseases – with products in Phase2 trials.

 

Ed Yaworski

VP, Pharmaceutical Development, Genevant Sciences
Ed Yaworski

Ed Yaworski is the Vice President of Pharmaceutical Development at Genevant Sciences where he helps lead the development of mRNA-LNP therapeutics. He has more than 25 years of experience in the pharmaceutical industry, including 17 years working with complex delivery systems for nucleic acids. Ed is a lead inventor on several key patents for nucleic acid-LNPs. He has strong CMC expertise with LNP-based therapeutics and he has contributed to clinical development in several areas including oncology, metabolic disorders, and infectious disease. Ed holds an MSc in Chemistry from the University of Manitoba.

Enrico Mastrobattista

Professor of Pharmaceutical Biotechnology & Delivery, Utrecht University
Enrico Mastrobattista

Prof. Mastrobattista obtained his Ph.D. in Advanced Drug Delivery from Utrecht University in 2001 and spent over two years as a Marie Curie postdoctoral fellow in the MRC-Laboratory of Molecular Biology in Cambridge (UK). He currently leads a research group that develops biomimetic drug delivery systems for the targeted delivery of therapeutic proteins, peptides and nucleic acids.
His main areas of expertise are drug delivery, pharmaceutical biotechnology and nanobiotechnology with a focus on the intracellular delivery of nucleic acids and genetic vaccines. Prof. Mastrobattista has published over 100 articles in scientific journals, contributed to several book chapters in pharmaceutical biotechnology and holds several patents to his name. In addition, he served as the scientific coordinator of IMI COMPACT, a public-private partnership with a total budget of 30 M€ in which 132 scientists from industy, SMEs and academia work together to find solutions for the delivery problem of biopharmaceuticals (www.compact-research.org). In 2013 he was awarded the prestigious Galien research price, The Netherlands, for his research on drug delivery (www.galenusprijs.nl). In addition, he is a board member of the Netherlands Society of Gene & Cell Therapy (www.nvgct.nl)
 

Francesca Ungaro

Associate Professor, University Of Napoli Federico Ii
Francesca Ungaro

Francesca Ungaro is Associate Professor of Pharmaceutical Technology at the Department of Pharmacy, School of Medicine of University of Napoli Federico II, Italy. She received her Degree in Pharmacy in 1999 and a Ph.D. in Pharmaceutical Sciences in 2003. Prof Ungaro’s research activity has been focused on the design and development of innovative drug delivery systems, with a special focus on nano- and micro-particulate carriers for lung delivery in cystic fibrosis. She coordinated and participated to several research projects funded by local institutions, Italian Ministry of research and research foundations. Results are documented by 75 peer-reviewed articles, 1 European patent, 4 book chapters, more than 100 presentations at symposia and 20 oral communications.

Heinrich Haas

VP RNA Formulation and Drug Developement , BioNTech RNA Pharmaceuticals
Heinrich Haas

Heinrich Haas has more than 20 years of experience in academic research and industrial pharmaceutical development. After he received his Ph.D. in physical chemistry, Dr. Haas researched lipid membranes and organized biomolecular systems. His professional focus is on colloidal/nanoparticulate formulations for targeted drug delivery with therapeutic and diagnostic applications. Before joining BioNTech RNA Pharmaceuticals GmbH (former Ribological GmbH), he was responsible for a variety of projects in biopharmaceutical research and development, ranging from the exploration of novel colloidal therapeutic and diagnostic carriers to up-scaling and development of market-compliant manufacturing methods for liposome products. After joining BioNTech RNA Pharmaceuticals GmbH in 2010, he helped build the formulation development and analytics unit, which develops formulations for delivery of RNA and small molecules. He has an active record of publications in peer-reviewed journals and patent applications in the field of drug delivery.

Katrien Remaut

Associate Professor, Ghent University
Katrien Remaut

Katrien Remaut

Associate Professor, Ghent University
Katrien Remaut

Katrien Remaut was born on 10/11/1978 in Ghent. In 2001, she graduated as Pharmacist with the greatest distinction and became doctor in pharmaceutical sciences in 2007. Katrien is author and co-author of >80 peer reviewed scientific publications in e.g. Advanced Drug Delivery Reviews, Journal of Controlled Release, ASC Nano, Acta Biomaterialia, … She received several scientific prices including the Price of the Royal Academy of Medicine for Scientific Research in Pharmacy. Katrien is alumni from the Young Academy in Flanders and EMBL. She was appointed tenure track professor at the Faculty of Pharmaceutical Sciences, Ghent University in 2014.

Remaut Katrien

Associate Professor, Ghent University
Remaut Katrien

Shalini Andersson

Chief Scientist New Therapeutic Modalities, AstraZeneca
Shalini Andersson

Shalini is currently Chief Scientist, New Therapeutic Modalities, in AstraZeneca and responsible for AstraZeneca Biopharmaceuticals therapeutic modality strategy that will enable expansion of druggable target space. Shalini has also the strategic responsibility for explorative activities and build of capabilities in the new therapeutic modalities area.
Shalini has broad experience in Pharmaceutical research as well as of strategic and management roles and drives several collaborations with external partners and academic groups across the globe.
Prior to this role, Shalini held several leadership roles within Cardiovascular, renal and metabolism.

Shalini received her PhD in 1989 at the University of Linköping, Sweden and has held various research and teaching positions at the University of Linköping prior to moving to industry. She is the author or co-author of over 45 peer reviewed articles, 2 book chapters and 4 patents.
 

Steve Pascolo

Founder and CEO, Miescher Pharma GmbH
Steve Pascolo

Trained as an immunologist at the Pasteur Institute (Paris, France), I used mouse models to test and develop mRNA-based vaccines (direct injection of mRNA) during my post-doc in Tuebingen, Germany. In 1999, I co-founded CureVac with Dr. Hoerr and Dr. von der Mulbe. I was CSO of the company from 2000 till 2006, developing the technology, implementing the worldwide first GMP production of mRNA and performing the worldwide first clinical studies where humans got injections of in vitro transcribed mRNA. In 2006 I joined the oncology department of the University Hospital of Zurich, Switzerland and continued the development of immunotherapies based on RNA. In 2008 I founded Miescher Pharma to support this work. In 2017, we implemented in Zurich an mRNA platform https://www.cancer.uzh.ch/en/Research/mRNA-Platform.html. In collaboration with several research and clinical departments in Zurich we test different mRNAs capable to enhance immunity against cancer. In addition, we developed modified RNA oligonucleotides to perform immunochemotherapies.

VENUE

Copthorne Tara Hotel

Scarsdale Place, Kensington, London, United Kingdom

The Copthorne Tara Hotel London Kensington is an elegant contemporary four-star hotel in prestigious Kensington, located just a two minutes walk from High Street Kensington underground station, making exploring easy. The hotel offers well-appointed and comfortable guest rooms combining Standard, Superior and Club accommodation. Club rooms offer iconic views over the city and include Club Lounge access for complimentary breakfast and refreshments. Guests can sample the authentic Singaporean, Malaysian and Chinese cuisine at Bugis Street, traditional pub fare at the Brasserie Restaurant & Bar or relax with a delicious drink at West8 Cocktail Lounge & Bar.

The Copthorne Tara Hotel boasts 745 square meters of flexible meeting space, consisting of the Shannon Suite and the Liffey Suite, ideal for hosting conferences, weddings and social events. Facilities include access to the business centre 24 hours a day, fully equipped fitness room, gift shop, theatre desk and Bureau de Change. With ample onsite parking outside the London congestion charge zone and excellent transport links via Heathrow Airport, the hotel is the perfect location for business or leisure stays. The hotel is within close proximity to the shops of High Street Kensington, Knightsbridge and Westfield London, Olympia Conference Centre, Royal Albert Hall, Kensington Palace and Hyde Park.

 

A number of our clients have been approached by third party organisations offering to book hotel rooms. We would advise that you do not book through them as they are not representing the SMi Group. SMi Group books all hotel rooms directly. If you are approached by a third party organisation then please contact us before making any bookings. If you have already booked a hotel room using a third party organisation, we would highly recommend contacting the hotel you were booked into to ensure a booking has been made for you. We would also advise you to please check the terms and conditions of the booking carefully.
HOTEL BOOKING FORM

Focus Day Programme

Download

SAVE TO


Outlook Calendar  OUTLOOK CALENDAR
Google Calendar  GOOGLE CALENDAR
ICal Calendar  ICAL CALENDAR
Yahoo! Calendar  YAHOO! CALENDAR

Copthorne Tara Hotel

Scarsdale Place
Kensington
London W8 5SR
United Kingdom

Copthorne Tara Hotel

The Copthorne Tara Hotel London Kensington is an elegant contemporary four-star hotel in prestigious Kensington, located just a two minutes walk from High Street Kensington underground station, making exploring easy. The hotel offers well-appointed and comfortable guest rooms combining Standard, Superior and Club accommodation. Club rooms offer iconic views over the city and include Club Lounge access for complimentary breakfast and refreshments. Guests can sample the authentic Singaporean, Malaysian and Chinese cuisine at Bugis Street, traditional pub fare at the Brasserie Restaurant & Bar or relax with a delicious drink at West8 Cocktail Lounge & Bar.

The Copthorne Tara Hotel boasts 745 square meters of flexible meeting space, consisting of the Shannon Suite and the Liffey Suite, ideal for hosting conferences, weddings and social events. Facilities include access to the business centre 24 hours a day, fully equipped fitness room, gift shop, theatre desk and Bureau de Change. With ample onsite parking outside the London congestion charge zone and excellent transport links via Heathrow Airport, the hotel is the perfect location for business or leisure stays. The hotel is within close proximity to the shops of High Street Kensington, Knightsbridge and Westfield London, Olympia Conference Centre, Royal Albert Hall, Kensington Palace and Hyde Park.

 

HOTEL BOOKING FORM

Title

SubTitle
speaker image

Content


Title


Description

Download


WHAT IS CPD?

CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

CPD AND PROFESSIONAL INSTITUTES

There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

GLOBAL CPD

Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

CPD Certificates

We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

Event Title

Headline

Text
Read More

I would like to speak at an event

I would like to attend an event

I would like to sponsor/exhibit at an event

SIGN UP OR LOGIN

Sign up
Forgotten Password?

Contact SMi GROUP LTD

UK Office
Opening Hours: 9.00 - 17.30 (local time)
SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
Registered in England No: 3779287 VAT No: GB 976 2951 71




Forgotten Password

Please enter the email address you registered with. We will email you a new password.

Thank you for visiting our event

If you would like to receive further information about our events, please fill out the information below.

By ticking above you are consenting to receive information by email from SMi.
Full details of our privacy policy can be found here https://www.smi-online.co.uk/privacy-legals/privacy-policy/.
Should you wish to update your contact preferences at any time you can contact us at data@smi-online.co.uk.
Should you wish to be removed from any future mailing lists please click on the following link http://www.smi-online.co.uk/opt-out